Groundbreaking Research Identifies Molecular Pathway Underlying Key Infection-Fighting Mechanism
--Pathway linked to inflammatory process with possible implications for cancer--
CAMBRIDGE, Mass., April 14 /PRNewswire-FirstCall/ -- Researchers at the University of Massachusetts Medical School (Worcester), Harvard University and Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) today announced the discovery of a new pathway underlying the body's innate immune response, which provides immediate, first-line defense against organisms such as viruses. The research, published in the online edition of Nature Immunology, represents an important advance in understanding how the immune system responds rapidly to infection before more specific responses - such as antibody production - are activated. The new discovery may also provide important insights into inflammatory processes and, possibly, into cancer cell proliferation.
The new pathway features two proteins known as I kappa B kinase epsilon and TANK-binding kinase-1. These proteins were shown to provide essential signals that lead to increased production of interferon and other proteins which stimulate defensive responses.
"The significance of this discovery goes beyond the innate immune response," said Tom Maniatis, Ph.D., department of molecular and cellular biology, Harvard University. "There are many similarities between this and inflammatory responses, as well as an important connection to the NF kappa B pathway."
The new research establishes an activation pathway for the body's innate immune response, a non-specific defensive response that is activated against infectious agents such as viruses and bacteria. The similarities between this response and inflammatory processes suggest that the new pathway could potentially be relevant for these processes as well. The connection with the NF kappa B pathway is also significant because of the central role that NF kappa B plays, not just in the innate immune response, but also in inflammation and cancer cell proliferation.
"We now understand more clearly how the body coordinates responses that are important in fighting infections and inflammation," said Katherine Fitzgerald, Ph.D., assistant professor at the University of Massachusetts Medical School.
"Some of the most advanced medical research today involves understanding the pathways of disease," said Robert I. Tepper, M.D., president of research and development at Millennium. "This provides new avenues of research that will hopefully one day lead to new ways of treating infectious disease as well as inflammation and possibly even cancer."
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, co- promotes INTEGRILIN® (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product candidates. The Company's research, development and commercialization activities are focused in four disease areas: cardiovascular, oncology, inflammation and metabolic. By applying its knowledge of the human genome, its understanding of disease mechanisms, and its industrialized technology platform, Millennium is developing breakthrough personalized medicine products. Headquartered in Cambridge, Mass. Millennium also has facilities in South San Francisco, Calif. and Cambridge, UK.
This press release contains "forward-looking statements," including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause our actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; the commercial success of INTEGRILIN; our ability to extinguish the convertible notes assumed in the COR acquisition; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Editor's Note: This release is available on Media section of Millennium website at www.millennium.com |
